GlassScriptPhysician profile
Sohil Patel
NPI 1437599099
$4,652.13
in general payments reported to CMS, 2019-2025
33 companies · $1,014 in 2025
The $1,014 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $619 · 2020: $444 · 2021: $370 · 2022: $357 · 2023: $860 · 2024: $987 · 2025: $1,014.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,862.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,862.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,012.04 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $601.28 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $574.18 | 2021-2025 | |
| Pfizer INC. | $461.74 | 2019-2025 | |
| Lilly USA, LLC | $285.00 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $264.04 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $145.58 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $143.15 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.57 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $118.70 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $102.14 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $91.98 | 2019-2025 | Gardasil 9, Capvaxive |
| Dexcom, INC. | $89.45 | 2023-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $85.57 | 2021-2023 | |
| Axsome Therapeutics, INC. | $81.69 | 2023-2025 | Auvelity, Sunosi |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $51.81 | 2019-2020 | |
| Corium, LLC | $50.01 | 2022-2025 | Azstarys |
| Dynavax Technologies Corporation | $49.46 | 2023-2024 | Heplisav-B |
| Biohaven Pharmaceuticals, INC. | $45.75 | 2021 | |
| Abiomed | $45.68 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $36.34 | 2023-2024 | Opsumit, Uptravi |
| Amgen INC. | $27.00 | 2019-2025 | Repatha |
| Daiichi Sankyo INC. | $19.85 | 2024 | Injectafer |
| Idorsia Pharmaceuticals US INC | $18.02 | 2022 | |
| Abbott Laboratories | $17.93 | 2023 | Freestyle Libre 2 |
| Shield Therapeutics INC | $17.83 | 2023 | Accrufer |
| Biohaven Pharmaceutical Holding Company LTD. | $17.53 | 2022 | |
| Ucb, INC. | $15.43 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $14.92 | 2024 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $13.12 | 2024 | Camzyos |
| Phadia US INC. | $12.01 | 2020 | |
| Eisai INC. | $12.01 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sohil Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.